- The research demonstrates that specific, human microbiome-derived bacteria assembled rationally into consortia can cooperatively enhance the responses to immune checkpoint inhibitors ... read more
Gossamer Bio announced terms for it's $230 Million IPO on 1/23/19. The company plans to offer 14.4 million shares at $16 per share. Insiders have expressed an interest in acquiring $100 million of... read more
Talee Bio, Inc. announced on 1/23/19 agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL... read more
BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR... read more
ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has partnered and established a collaboration with the Ladak Laboratory at Western University,... read more
According to this regulatory filing, Pappas has raised a new $85.7 million investment... read more
The Janssen Pharmaceutical Companies of Johnson & Johnson... read more
Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS... read more
... read more
Numerate, Inc. announced on 1/7/19 a multi-target research collaboration with Lundbeck Pharmaceutical to identify clinical candidates for the treatment of disorders in the central nervous system,... read more
Atlantic Therapeutics announced on 1/7/19 that it has closed €28 million in Series B funding to continue its rapid growth trajectory.
Having recently gained FDA clearance for its INNOVO® ... read more
Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions announced on 1/4/19 the closing of a $... read more
Ablative Solutions, Inc. announced on 1/3/19 the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar... read more
Wave Life Sciences Ltd. (NASDAQ: WVE announced on 1/3/19 that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne muscular dystrophy (DMD) clinical program has been selected for... read more
Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for MYO-102, a novel gene therapy candidate for alpha-... read more
Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed... read more
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide)... read more